Left ventricular function and N‐terminal pro b‐type natriuretic peptide levels in women with hypertensive disorders of pregnancy: A prospective observational study

Abstract

Pre-eclampsia is a syndrome occurring in pregnancy that involves virtually every organ system. A systematic review by WHO determined that in developed countries, 16% of maternal deaths were attributed to hypertensive disorders. 1 Almost one in four mothers with pre-eclampsia/eclampsia is at risk of persistent hypertension after the puerperium. 2 Pre-eclampsia is seen to recur in pregnancies at a rate of 20%-25%. 3 In India, the incidence of pre-eclampsia is reported to be 8%-10% among pregnant women. 4 In a study by Manjusha Sajith in Pune including 1330 women visiting the antenatal clinic, the prevalence of hypertensive disorders of pregnancy (HDP) was 7.8% (104 women) with pre-eclampsia in 5.6% (75 women) of the study population. 5 The maternal outcomes are more likely to be adverse if preeclampsia occurs before 32 weeks of pregnancy or in association with pre-existing comorbidities such as renal disease/ pregestational type 1 or type 2 diabetes mellitus. 6

Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia

“…To gain insights into the identified proteins’ dynamics during hypertensive vs normotensive pregnancies, we performed a systematic review of studies reporting observational associations of the prioritized proteins with HDPs. Forty-three studies met our inclusion criteria (eFigure 3 in Supplement 1), encompassing 9749 pregnant individuals with protein measurements who enrolled from 1998 to 2020 in their respective studies. Of those, 3122 individuals (32.0%) experienced an HDP, including 939 (9.6%) with gestational hypertension, 2167 (22.2%) with preeclampsia, and 16 (0.2%) without information on HDP subtype.…”

“…Of those, 3122 individuals (32.0%) experienced an HDP, including 939 (9.6%) with gestational hypertension, 2167 (22.2%) with preeclampsia, and 16 (0.2%) without information on HDP subtype. The most frequently tested biomarker was NT-proBNP (n = 8940; 30 studies), followed by Gal-3 (n = 921; 11 studies), HSP27 (n = 363; 5 studies), and CD40 (n = 81; 2 studies). CSTB and ECP were both evaluated by a single study including 66 participants.…”